medigraphic.com
ISSN 2992-8036 (Digital)
ISSN 2306-4102 (Impreso)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2013, Número S1

<< Anterior Siguiente >>

Acta Ortop Mex 2013; 27 (S1)


Tratamiento antibiótico oral

Idioma: Español
Referencias bibliográficas: 61
Paginas: 154-159
Archivo PDF: 151.71 Kb.


FRAGMENTO

Introducción

Este panel ha revisado la indicación y duración de los antibióticos orales para la infección articular periprotésica (IAP) en las siguientes situaciones:

1) En la IAP (aguda, temprana o tardía) tratada con desbridamiento sin retiro del implante y con recambio de los componentes modulares, siempre y cuando los componentes se puedan retirar de forma segura. En general, estas infecciones no requieren tratamiento antibiótico supresor (TAS), entendida como el empleo de antibióticos orales para el tratamiento de la recidiva de los síntomas y/o falla de la función en pacientes portadores de material protésico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lora-Tamayo J, Murillo O, Iribarren JA, et al: A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2012; 56(2): 182-194.

  2. Silva M, Tharani R, Schmalzried TP: Results of direct exchange or debridement of the infected total knee arthroplasty. Clin Orthop Relat Res. 2002; (404): 125-131.

  3. Achermann Y, Eigenmann K, Ledergerber B, et al: Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection. 2013; 41(2): 431-437.

  4. Sia IG, Berbari EF, Karchmer AW: Prosthetic joint infections. Infect Dis Clin North Am. 2005; 19(4): 885-914.

  5. Berbari EF, Osmon DR, Duffy MC, et al: Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis. 2006; 42(2): 216-223.

  6. Fehring TK, Odum SM, Berend KR, et al: Failure of irrigation and debridement for early postoperative periprosthetic infection. Clin Orthop Relat Res. 2012; 471(1): 250-257.

  7. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A: Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 2009; 53(3): 1142-1148.

  8. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999; 37(6): 1771-1776.

  9. Garrigos C, Murillo O, Euba G, et al: Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(12): 5251-5256.

  10. Monzon M, Oteiza C, Leiva J, Lamata M, Amorena B: Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn Microbiol Infect Dis. 2002; 44(4): 319-324.

  11. Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC: Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(10): 4589-4593.

  12. Zimmerli W, Frei R, Widmer AF, Rajacic Z: Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994; 33(5): 959-967.

  13. Barberan J, Aguilar L, Carroquino G, et al: Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med. 2006; 119(11): 993 e997-910.

  14. Byren I, Bejon P, Atkins BL, et al: One hundred and twelve infected arthroplasties treated with ‘DAIR’ (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother. 2009; 63(6): 1264-1271.

  15. Cobo J, Miguel LG, Euba G, et al: Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect. 2011; 17(11): 1632-1637.

  16. El Helou OC, Berbari EF, Lahr BD, et al: Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis. 2010; 29(8): 961-967.

  17. Giulieri SG, Graber P, Ochsner PE, Zimmerli W: Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection. 2004; 32(4): 222-228.

  18. Laffer RR, Graber P, Ochsner PE, Zimmerli W: Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect. 2006; 12(5): 433-439.

  19. Senneville E, Joulie D, Legout L, et al: Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011; 53(4): 334-340.

  20. Soriano A, Garcia S, Bori G, et al: Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbio lInfect. 2006; 12(9): 930-933.

  21. Soriano A, Garcia S, Ortega M, et al: Treatment of acute infection of total or partial hip arthroplasty with debridement and oral chemotherapy. MedClin (Barc). 2003; 121(3): 81-85.

  22. Vílchez F, Martínez-Pastor JC, García-Ramiro S, et al: Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect. 2011; 17(3): 439-444.

  23. Anderl JN, Zahller J, Roe F, Stewart PS: Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2003; 47(4): 1251-1256.

  24. Nijland HM, Ruslami R, Suroto AJ, et al: Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007; 45(8): 1001-1007.

  25. Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N: Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother. 2010; 54(1): 88-92.

  26. Gandelman K, Zhu T, Fahmi OA, et al: Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011; 51(2): 229-236.

  27. Tornero E, Garcia-Oltra E, Garcia-Ramiro S, et al: Prosthetic joint infections due to Staphylococcus aureus and coagulase-negative staphylococci. Int J Artif Organs. 2012; 35(10): 884-892.

  28. Bradbury T, Fehring TK, Taunton M, et al: The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty. 2009; 24(6 Suppl): 101-104.

  29. Ferry T, Uckay I, Vaudaux P, et al: Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis. 2010; 29(2): 171-180.

  30. Salgado CD, Dash S, Cantey JR, Marculescu CE: Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. 2007; 461: 48-53.

  31. Bassetti M, Vitale F, Melica G, et al: Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005; 55(3): 387-390.

  32. Gomez J, Canovas E, Banos V, et al: Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother. 2011; 55(9): 4308-4310.

  33. Rao N, Hamilton CW: Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007; 59(2): 173-179.

  34. Rao N, Ziran BH, Hall RA, Santa ER: Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res. 2004; (427): 67-71.

  35. Razonable RR, Osmon DR, Steckelberg JM: Linezolid therapy for orthopedic infections. Mayo Clin Proc. 2004; 79(9): 1137-1144.

  36. Soriano A, Gomez J, Gomez L, et al: Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis. 2007; 26(5): 353-356.

  37. Pea F, Furlanut M, Cojutti P, et al: Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010; 54(11): 4605-4610.

  38. Peel TN, Buising KL, Dowsey MM, et al: Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother. 2012; 57(1): 350-355.

  39. Stein A, Bataille JF, Drancourt M, et al: Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother. 1998; 42(12): 3086-3091.

  40. Wu WS, Chen CC, Chuang YC, et al: Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant Staphylococcus aureus. J Microbiol Immunol Infect. 2013; 46(2): 89-95.

  41. Meehan AM, Osmon DR, Duffy MC, Hanssen AD, Keating MR: Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis. 2003; 36(7): 845-849.

  42. Odum SM, Fehring TK, Lombardi AV, et al: Irrigation and debridement for periprosthetic infections: does the organism matter? J Arthroplasty. 2011; 26(6 Suppl): 114-118.

  43. El Helou OC, Berbari EF, Marculescu CE, et al: Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin Infect Dis. 2008; 47(7): 903-909.

  44. Holmberg A, Morgelin M, Rasmussen M: Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother. 2012; 67(2): 433-439.

  45. Aboltins CA, Dowsey MM, Buising KL, et al: Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbio lInfect. 2011; 17(6): 862-867.

  46. Martinez-Pastor JC, Munoz-Mahamud E, Vilchez F, et al: Outcome of acute prosthetic joint infections due to Gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother. 2009; 53(11): 4772-4777.

  47. San Juan R, Garcia-Reyne A, Caba P, et al: Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother. 2010; 54(12): 5161-5166.

  48. Daver NG, Shelburne SA, Atmar RL, et al: Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect. 2007; 54(6): 539-544.

  49. Euba G, Murillo O, Fernandez-Sabe N, et al: Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother. 2009; 53(6): 2672-2676.

  50. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME: Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976). 2008; 33(10): E297-304.

  51. Osmon DR, Berbari EF, Berendt AR, et al: Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(1): e1-e25.

  52. Zimmerli W, Trampuz A, Ochsner PE: Prosthetic-joint infections. N Engl J Med. 2004; 351(16): 1645-1654.

  53. Edmiston CE Jr, Goheen MP, Seabrook GR, et al: Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg. 2006; 192(3): 344-354.

  54. Bernard L, Legout L, Zurcher-Pfund L, et al: Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect. 2010; 61(2): 125-132.

  55. Bejon P, Byren I, Atkins BL, et al: Serial measurement of the C-reactive protein is a poor predictor of treatment outcome in prosthetic joint infection. J Antimicrob Chemother. 2011; 66(7): 1590-1593.

  56. Bengtson S, Knutson K: The infected knee arthroplasty. A 6-year follow-up of 357 cases. Acta Orthop Scand. 1991; 62(4): 301-311.

  57. Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J: Infection control rate of irrigation and debridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011; 469(11): 3043-3048.

  58. Lentino JR: Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis. 2003; 36(9): 1157-1161.

  59. Marculescu CE, Berbari EF, Hanssen AD, et al: Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis. 2006; 42(4): 471-478.

  60. Rao N, Crossett LS, Sinha RK, Le Frock JL: Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res. 2003(414): 55-60.

  61. Segreti J, Nelson JA, Trenholme GM: Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998; 27(4): 711-713.




2020     |     www.medigraphic.com